<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122913</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-TRK-14001</org_study_id>
    <nct_id>NCT02122913</nct_id>
  </id_info>
  <brief_title>Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, Phase 1 study of orally administered larotrectinib in
      adult subjects with advanced solid tumors and a NTRK1, NTRK2, or NTRK3 gene fusion that have
      progressed or are non responsive to available therapies and for which no standard or
      available curative therapy exists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted in 2 parts: an initial dose escalation phase of larotrectinib in
      subjects with advanced solid tumors. This will be followed by an expansion phase in solid
      tumor subjects with an NTRK fusion. During the escalation phase, larotrectinib will be taken
      once daily (QD) or twice daily (BID). During the expansion phase, the larotrectinib dose
      selected from the escalation phase will be explored in approximately 40 additional subjects.
      Enrollment into the dose esclation portion of this study has been completed and is currently
      closed to enrollment. Patients will continue to be considered for enrollment into the dose
      expansion portion of this study.

      The objectives of the dose escalation phase are to determine the safety, tolerability,
      pharmacokinetic profile, and recommended dose of orally administered larotrectinib. The
      objectives of the expansion phase are to better characterize the safety and efficacy of
      larotrectinib in patients with NTRK fusions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) and/or the appropriate dose for further clinical investigation.[Escalation]</measure>
    <time_frame>32 months [Actual]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>19 months [Estimated]</time_frame>
    <description>Assessed by clinical review of all relevant parameters including AEs, SAEs, laboratory values, virals signs, ECG results, concomitant medications and thyroid function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of LOXO-101 including Cmax, Tmax, t1/2, and AUC following both QD and BID dosing.</measure>
    <time_frame>19 months [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>As assessed using RECIST 1.1 or RANO, as appropriate, per tumor type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Larotrectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation- Multiple doses of larotrectinib.
Expansion- The MTD dose and/or the appropriate dose for furher clinical investigation of larotrectinib found during the Escalation Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Larotrectinib</intervention_name>
    <description>Oral larotrectinib</description>
    <arm_group_label>Larotrectinib</arm_group_label>
    <other_name>LOXO-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Escalation Phase [Inclusion]

          -  Locally advanced or metastatic adult solid tumor that has progressed or was
             nonresponsive to available therapies, are unfit for standard chemotherapy or for which
             no standard or available curative therapy exists;

          -  ECOG score of 0, 1 or 2;

          -  Adequate hematologic, hepatic, and renal function;

        Expansion Phase [Inclusion]

          -  Escalation Phase inclusion criteria

          -  Evidence of the NTRK fusion as previously determined with prior testing from a
             Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent certified
             laboratory.

        Exclusion (for both Escalation and Expansion)

        â€¢ Current treatment with a strong cytochrome P450 (CYP) 3A4 inhibitor or inducer (EIAEDs
        and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Cox, PharmD, , MHSc, BCOP</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-NTRK-123</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>11100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRK</keyword>
  <keyword>TRKA</keyword>
  <keyword>TRKB</keyword>
  <keyword>TRKC</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>larotrectinib</keyword>
  <keyword>NTRK fusion positive</keyword>
  <keyword>NTRK gene rearrangements</keyword>
  <keyword>NTRK1 fusion</keyword>
  <keyword>NTRK2 fusion</keyword>
  <keyword>NTRK3 fusion</keyword>
  <keyword>NTRK1 gene rearrangement</keyword>
  <keyword>NTRK2 gene rearrangement</keyword>
  <keyword>NTRK3 gene rearrangement</keyword>
  <keyword>ETV6-NTRK3</keyword>
  <keyword>fusion</keyword>
  <keyword>tumors</keyword>
  <keyword>solid tumors</keyword>
  <keyword>CNS tumors</keyword>
  <keyword>central nervous system tumors</keyword>
  <keyword>TRK fusion</keyword>
  <keyword>ETV6</keyword>
  <keyword>ETV6 fusion</keyword>
  <keyword>ETV6 gene rearrangement</keyword>
  <keyword>solid CNS tumor</keyword>
  <keyword>Advanced CNS tumor</keyword>
  <keyword>Primary CNS tumor</keyword>
  <keyword>Metastatic CNS tumor</keyword>
  <keyword>LOXO-101</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

